Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Lack of trading volume allows the share price to drift down

<< Previous

Bullboard Posts

Next >>

Comment by biorunon May 05, 2021 10:53am

128 Views

Post# 33131761

RE:RE:RE:Lack of trading volume allows the share price to drift down

Possible, and agree with their reputation to stay on date.

The probability of just one significant milestone being reached in the next 8-10 weeks, maybe earlier, is reasonably fair. The target date was extended to achieve all milestones listed. They won't announce them all the on the Wednesday of the 12th week.

<< Previous

Bullboard Posts

Next >>

Corus reports Q1 profit drop in the face of falling revenue